Prostaglandin E2 enhances, and leukotriene C4 inhibits, interleukin-1 inhibition of WEHI-3B cell growth.
Human recombinant interleukin-1 (HrIL-1) inhibited WEHI-3B cell growth in a dose-related manner (10-10,000 U/ml). Prostaglandin E2 at high concentrations (1000 ng/ml) also inhibited cell growth. When added together, HrIL-1 and prostaglandin E2 inhibited WEHI-3B growth in a synergistic manner (HrIL-1 concentrations of 10-10,000 U/ml and prostaglandin E2 concentrations of 10-1000 ng/ml). In contrast to the effects of the cyclooxygenase metabolite of arachidonic acid leukotriene C4, a lipoxygenase metabolite, reversed the cytostatic action of HrIL-1.
Elliott
G R
GR
Department of Pharmacology, Medical Faculty, Erasmus University Rotterdam, The Netherlands.
Tak
C
C
Bonta
I L
IL
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D002460:Cell Line; D015232:Dinoprostone / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D007975:Leukotriene B4 / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D013189:SRS-A / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000378:metabolism
D000276:Adjuvants, Immunologic; D006131:Growth Inhibitors; D007375:Interleukin-1; D011994:Recombinant Proteins; D013189:SRS-A; D007975:Leukotriene B4; D013929:Thromboxane B2; D015232:Dinoprostone